

(Attachment)

This attachment has been updated from the announcement issued on January 30, 2025, titled “Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026.”

1. Changes in Appointment and Titles of Representative Directors

Name	New Title (planned)	Current Title
Julie Kim	Representative Director, President & Chief Executive Officer*	CEO-Elect
Christophe Weber	Retirement	Representative Director, President & Chief Executive Officer

* Subject to election and appointment at the 150th Ordinary General Meeting of Shareholders and Board of Directors meeting on June 24, 2026.

2. Biography of Newly Appointed Representative Director

Name (Date of Birth)	Business Experience	Number of ADSs Held*	
Julie Kim (June 6, 1970)	June 2016	Joined Shire plc	173,773 ADSs
	June 2016	Head of International Value Demonstration & Access	
	May 2018	Head of Global Hematology Franchise	
	January 2019	Joined Takeda Pharmaceutical Company Limited	
	January 2019	President, Plasma-Derived Therapies Business Unit	
	April 2022	President, U.S. Business Unit, and U.S. Country Head	
	August 2025	President, U.S. Business Unit, U.S. Country Head and Interim Head, Global Portfolio Division	
	September 2025	Director and Chief Executive Officer, Takeda Pharmaceuticals U.S.A., Inc. (present)	
	November 2025	Interim Head, Global Portfolio Division	
January 2026	CEO-Elect (present)		

* There are no ordinary shares held as of the filing date.

3. Effective Date of Changes (planned)

June 24, 2026